Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Gilead Sciences (GILD) Q4 Revenue Tops Views, Offers Guidance
February 6, 2018 4:03 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.74 billion.
GUIDANCE:
Gilead Sciences sees FY2018 revenue of $20-21 billion, versus the consensus of... More
